Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes

To the Editor: In the SURPASS-2 trial (A Study of Tirzepatide [LY3298176] versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes), Frías et al. (Aug. 5 issue)1 report that treatment with tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, resulted in better glycemic control and greater weight loss than semaglutide in patients with type 2 diabetes mellitus. A closer look at the clinical characteristics of the enrolled patients at baseline reveals that the mean systolic blood pressure across the treatment groups ranged from 129.96 to 131.47 mm Hg. In the . . .

More Info

By Betty C. Giordano

Welcome to my site. My name is Betty C. Giordano and I am a blogger of everything related to mobile, news, events and reality in general. I hope you enjoy reading my content.

Leave a Reply